Simcere Pharmaceutical Group Limitedの主要な財務諸表は何ですか?
02096.HKの主要な財務比率は何ですか?
Simcere Pharmaceutical Group Limitedの収益はセグメントまたは地域別にどのように分けられていますか?
Simcere Pharmaceutical Group Limitedは収益を上げていますか?
Simcere Pharmaceutical Group Limitedに負債はありますか?
Simcere Pharmaceutical Group Limitedの発行済株式数は何株ですか?
主要データ
前終値
$11.62
始値
$11.62
当日レンジ
$11.44 - $11.78
52週レンジ
$6.2 - $15.08
取引高
11.0M
平均取引高
8.2M
1株当たり利益(TTM)
0.40
配当利回り
--
時価総額
$30.2B
SIMCERE PHARMAとは何ですか?
Simcere Pharmaceutical Group Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products. The company is headquartered in Nanjing, Jiangsu and currently employs 6,815 full-time employees. The company went IPO on 2020-10-27. The firm's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The firm also produces various drugs, including Endostar used for oncology. The firm is also involved in providing promotion services for third-party drugs sold by medical institutions. The firm mainly conducts its businesses in the domestic market and overseas markets.